Results 31 to 40 of about 57,995 (263)

Meta-analysis on the effects of octreotide on tumor mass in acromegaly. [PDF]

PLoS ONE, 2012
BACKGROUND: The long-acting somatostatin analogue octreotide is used either as an adjuvant or primary therapy to lower growth hormone (GH) levels in patients with acromegaly and may also induce pituitary tumor shrinkage.
Andrea Giustina, Gherardo Mazziotti, Valter Torri, Maurizio Spinello, Irene Floriani, Shlomo Melmed   +5 more
doaj   +1 more source

Pasireotide for the Medical Management of Feline Hypersomatotropism [PDF]

, 2015
BACKGROUND: Feline hypersomatotropism (HST) is a cause of diabetes mellitus in cats. Pasireotide is a novel multireceptor ligand somatostatin analog that improves biochemical control of humans with HST.
Abraham, Adams, Alt, Appleton, Bhayana, Bruns, Castillo, Church, Colao, Colao, Cuevas-Ramos, Fedele, Fernandez-Rodriguez, Fougner, Golor, Henry, Hofland, Juul, Katznelson, Kvols, Lamb, Lamberts, Maxwell, Meij, Miller, Murray, Myers, Niessen, Niessen, Niessen, Niessen, Petrus, Polska, Rand, Ray, Schmid, Schmid, Sheppard, Slingerland, Sohmiya, Starkey, Stolk, Taboada, Wajchenberg, Zatelli, Zou   +45 more
core   +2 more sources

ANNIVERSARY REVIEW: Octreotide, 40 years later.

European Journal of Endocrinology, 2019
Octreotide remains 40 years after its development a drug, which is commonly used in the treatment of acromegaly and GEP-NETs. Very little innovation that competes with this drug occurred over this period. This review discusses several aspects of 40 years
S. Lamberts, L. Hofland
semanticscholar   +1 more source

Octreotide in Intestinal Lymphangiectasia: Lack of a Clinical Response and Failure to Alter Lymphatic Function in a Guinea Pig Model

Canadian Journal of Gastroenterology, 2004
Intestinal lymphangiectasia, which can be classified as primary or secondary, is an unusual cause of protein-losing enteropathy. The main clinical features include edema, fat malabsorption, lymphopenia and hypoalbuminemia.
S Makhija, P-Y vod der Weid, J Meddings, SJ Urbanski, PL Beck   +4 more
doaj   +1 more source

The somatostatin analogue octreotide inhibits growth of small intestine neuroendocrine tumour cells. [PDF]

PLoS ONE, 2012
Octreotide is a widely used synthetic somatostatin analogue that significantly improves the management of neuroendocrine tumours (NETs). Octreotide acts through somatostatin receptors (SSTRs).
Su-Chen Li, Cécile Martijn, Tao Cui, Ahmed Essaghir, Raúl M Luque, Jean-Baptiste Demoulin, Justo P Castaño, Kjell Öberg, Valeria Giandomenico   +8 more
doaj   +1 more source

Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis [PDF]

, 2007
Hepatorenal syndrome (HRS) is a serious complication of end-stage liver disease, occurring mainly in patients with advanced cirrhosis and ascites, who have marked circulatory dysfunction,1 as well as in patients with acute liver failure.2 In spite of its
Angeli P, Arroyo V, BERNARDI, MAURO, Blendis L, Di Bona G, Garcia Tsao G, Gerbes A, Ginès P, Guevara M, Gülberg V, Henriksen JH, Kamath P, Lee S, Moore K, Moreau R, Mullen K, Ortega R, Ruiz del Arbol L, Salerno F, Sanyal A, Terg R., Wong F   +21 more
core   +4 more sources

Efficacy and safety of octreotide treatment for diazoxide‐unresponsive congenital hyperinsulinism in China

Pediatric Investigation, 2020
Importance Octreotide is an off‐label medicine for congenital hyperinsulinism (CHI), but is currently widely used for treatment of patients with CHI. Thus far, variable efficacy and adverse effects have been reported for octreotide. Objective The present
Bingyan Cao, Wu Di, Chang Su, Jiajia Chen, Xuejun Liang, Min Liu, Wenjing Li, Xiaoqiao Li, Chunxiu Gong   +8 more
doaj   +1 more source

Pasireotide Long-Acting Release Treatment for Diabetic Cats with Underlying Hypersomatotropism [PDF]

, 2017
BACKGROUND: Long‐term medical management of hypersomatotropism (HS) in cats has proved unrewarding. Pasireotide, a novel somatostatin analogue, decreases serum insulin‐like growth factor 1 (IGF‐1) and improves insulin sensitivity in cats with HS when ...
Abraham, Berg, Bruns, Church, Colao, Colao, Combes, Cozzi, Dowling, Dunning, Feelders, Freda, Gadelha, Henry, Hofland, Hubina, Hussaini, Jaffe, Katznelson, Kurosaki, Lamb, Laron, Ma, Meij, Meij, Myers, Niessen, Niessen, Niessen, Patel, Petersenn, Peterson, Reubi, Reusch, Reusch, Sathyapalan, Schaefer, Scudder, Shanik, Slingerland, Slingerland, Theodoropoulou, Tyson, Zambre   +43 more
core   +2 more sources

Site‐Selective Peptide and Protein Functionalization with Cyclopropenium Cations

Angewandte Chemie, EarlyView.
A cysteine‐selective bioconjugation using aromatic cyclopropenium cations is reported. The reaction proceeds rapidly under aqueous conditions, enabling site‐selective installation of tetrasubstituted cyclopropene rings on peptides and proteins. The method shows preference for internal cysteines and provides conjugates that serve as efficient radical ...
Adriana Faraone, Matteo Balletti, Aliénor Jeandin, Hang‐Fei Tu, Viktoria A. Ikonnikova, Laura S. Sojka, Marcos G. Suero   +6 more
wiley   +2 more sources

Octreotide may improve pharyngocutaneous fistula healing through downregulation of cystatins: A pilot study

Laryngoscope Investigative Otolaryngology, 2023
Background Pharyngocutaneous fistula (PCF) and salivary leaks are well known complications of head and neck surgery. The medical management of PCF has included the use of octreotide without a well‐defined understanding of its therapeutic mechanism.
Jonathan Cohen, William Reed, Matthew W. Foster, Russel R. Kahmke, Daniel J. Rocke, Liana Puscas, Trinitia Y. Cannon, Walter T. Lee   +7 more
doaj   +1 more source